Description
Glifempa-Lin-XR Tablets (30’s)
Glifempa-Lin-XR is an extended-release oral antidiabetic combination containing Empagliflozin, Linagliptin, and Metformin XR. It is designed for adults with type 2 diabetes mellitus who require multiple mechanisms of action for optimal glycemic control.
Key Features:
-
Triple-action formula:
-
Empagliflozin (SGLT2 inhibitor): Promotes glucose excretion via urine.
-
Linagliptin (DPP-4 inhibitor): Enhances insulin secretion and lowers glucagon.
-
Metformin XR (Extended Release): Reduces hepatic glucose production and improves insulin sensitivity.
-
-
Once-daily extended-release formulation for steady 24-hour blood sugar control.
-
May assist with weight management and has a low risk of hypoglycemia.
-
May provide cardiovascular and renal benefits in patients with comorbidities.
Indications:
-
For the treatment of type 2 diabetes mellitus in adults.
-
Used when diet, exercise, and dual therapy do not provide adequate glycemic control.
-
Can be part of a comprehensive diabetes management plan.
Dosage & Administration:
-
Take once daily with food, preferably the evening meal to reduce gastrointestinal discomfort.
-
Dosage individualized based on prior treatment and blood glucose levels.
-
Regular monitoring of blood sugar and kidney function is essential.
Precautions:
-
Not suitable for type 1 diabetes or diabetic ketoacidosis.
-
Use with caution in renal or hepatic impairment.
-
Monitor for signs of lactic acidosis, urinary/genital infections, or pancreatitis.
-
Inform healthcare providers about all medications being used.
Possible Side Effects:
-
Gastrointestinal upset (due to Metformin), especially at initiation
-
Urinary or genital tract infections
-
Headache, fatigue
-
Rare: hypoglycemia, lactic acidosis, pancreatitis
Storage:
-
Store in a cool, dry place below 25°C.
-
Keep out of reach of children.
Reviews
There are no reviews yet.